Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
85 hedge funds and large institutions have $123M invested in Antares Pharma, Inc. in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 15 closing their positions.
7% less funds holding
Funds holding: 91 → 85 (-6)
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
29% less capital invested
Capital invested by funds: $174M → $123M (-$51.1M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
92% less call options, than puts
Call options by funds: $41K | Put options by funds: $498K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.48M |
| 2 |
WHI
William Harris Investors
Chicago,
Illinois
|
+$2.48M |
| 3 |
BC
Broadfin Capital
New York
|
+$2.26M |
| 4 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$687K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$355K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$11.2M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$4.32M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$3.41M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$1.75M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$978K |
ATRS Hedge Fund Activity: Q2 2014 in Review
85 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2014, worth a combined $123M — down 29% from $174M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ATRS and 9 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 27 added.
The largest buyer was Millennium Management, adding an estimated $5.48M. The largest seller was OrbiMed, exiting entirely with an estimated $11.2M sold.
- 85 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2014, down from 91 in Q1 2014.
- Funds reported $123M of Antares Pharma, Inc. stock for Q2 2014, down 29% quarter-over-quarter.
- 9 funds opened new Antares Pharma, Inc. positions in Q2 2014 and 15 closed out, a net change of -6 holders.
- The largest Antares Pharma, Inc. buyer in Q2 2014 was Millennium Management, an estimated $5.48M added.
- The largest Antares Pharma, Inc. seller in Q2 2014 was OrbiMed, an estimated $11.2M sold.
Based on aggregated 13F filings for Q2 2014.